Navigation Links
Prometheus Licenses COLAL-PRED(R) From Alizyme
Date:11/29/2007

SAN DIEGO, Nov. 29 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical company today announced that it has entered into an exclusive license agreement to develop and commercialize COLAL-PRED(R) for gastrointestinal diseases or other applications in North America from Alizyme Therapeutics Limited, a wholly owned subsidiary of Alizyme plc. COLAL-PRED has a unique competitive profile based on Alizyme's proprietary COLAL(R) drug delivery technology which is designed to release a drug, in this case an anti- inflammatory steroid, in the colon to provide efficacy but without the undesirable side effects usually associated with the use of systemic steroids.

Under the terms of the agreement, Prometheus made an up-front payment which may be followed by additional payments on the successful achievement of future development milestones, including U.S. Food and Drug Administration (FDA) approval of the product. Prometheus will also sponsor substantially all of the clinical development costs for COLAL-PRED in North America and pay royalty rates which increase with higher annual net sales levels of COLAL-PRED. Subject to the successful completion of clinical trials, Prometheus anticipates that it will file a new drug application (NDA) with the FDA in 2011.

"We are delighted to partner with Prometheus in North America for the development and commercialization of COLAL-PRED," said Tim McCarthy, Alizyme's Chief Executive Officer. "As a leader in the provision of therapeutics and complementary diagnostics to gastrointestinal specialists throughout the United States, we believe Prometheus is uniquely positioned to maximize the commercial potential of COLAL-PRED. This partnership with Prometheus marks an important step in the commercialization of COLAL-PRED in North America in parallel with our own development and commercialization plans in Europe and the rest of the world."

"We are excited to have entered into this partnership with Alizy
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
3. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
4. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
5. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
6. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
7. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
8. Syngenta Licenses Chromatin Gene Stacking Technology
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Look inside ... hard-working items for the lab, from fluid handling to ... (GIS)—ready to ship when you order. , Preferred ... Pumps , from the L/S® model for precise flow ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... facilities, HR,occupational health, and safety professionals are already ... June 24, 2008 at the,American Conference Center, New ... the EEC, is,providing a new one-day conference format ... EEC alumni. The new format, which provides a ...
... (OTC Bulletin Board: DSCI), a provider of advanced wound ... an increase of 22 percent,over the $27.9 million reported ... due primarily to the costs of bringing in new ... sales staffs, the,Company reported a loss of $2.3 million ...
... April 1, 2008 Piedmont Heart Institute (PHI),expands ... cardiovascular,physician practice, Cardiology of Georgia, P.C. (COG), through ... 2008. With eight,locations including Buckhead, Canton, Fayetteville and ... under the Piedmont Heart Institute and an,important addition ...
Cached Biology Technology:Eastern Ergonomics Conference, June 24 in New York City; New One-Day Format, Focus on Core Ergonomics Education 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5Piedmont Heart Institute Welcomes Cardiology of Georgia 2Piedmont Heart Institute Welcomes Cardiology of Georgia 3Piedmont Heart Institute Welcomes Cardiology of Georgia 4
(Date:7/9/2014)... Bacteria found in the bladders of healthy women ... form of incontinence, according to researchers from Loyola ... These findings, published July 9, 2014, in the ... , suggest that bacterial communities may play a ... incontinence (UUI) is a common, yet poorly understood, ...
(Date:7/9/2014)... the geographic ranges in which animals can be found, ... parasites. Does an increased range for a host mean ... necessarily, says a team of UC Santa Barbara scientists, ... study published in the Journal of Biogeography , ... the opposite may happen: Hosts may actually lose their ...
(Date:7/9/2014)... behind nature,s ability to split the water molecule ... of artificial photosynthesis for clean, green and renewable ... of scientists led by researchers with the Lawrence ... National Accelerator Laboratory. , Working at SLAC,s ... powerful x-ray laser, the researchers were able to ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3
... long since been a standard animal model for cancer research, ... average and high incidence of cancer. Naked mole rats however, ... rodent has a maximum lifespan exceeding 30 years and most ... single incident of cancer has been detected makes the naked ...
... 31, 2013 Nimbus-Online, Inc. released today a white paper ... reactions to any part of a package while it is ... zero in on specific parts of something a person is ... huge advancement in the science of optical, neural and biometric ...
... dioxide deep underground could at the same be used to ... reservoirs, thus offsetting some of the environmental impact of burning ... the peer-reviewed International Journal of Oil, Gas and Coal ... extracting previously untapped fossil fuel reserves has been in the ...
Cached Biology News:The naked mole-rat's secret to staying cancer free 2If you see a puppy on a package, are you more likely to buy it? 2Sequestration and fuel reserves 2
Tube-O-DIALYZER Floats, small....
Feline Rhinotracheitis Virus...
Ezrin/Radixin/Moesin Antibody...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: